Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions

What's in – and what fell out of – the massive US stimulus package.

Overall, the massive legislation coronavirus that passed the Senate and is headed to a House vote and then President Trump's desk is a mixed blessing for the pharmaceutical industry, containing an important proviso related to drug pricing, but missing several potentially significant policy changes that were included in draft legislation at the beginning of the process. Below is a look at some of the major provisions in various versions of the bill; manufacturing elements of the legislation will be addressed in a subsequent table.

Open Media

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet